LGG-44. A PHASE I DOSE ESCALATION TRIAL OF THE MEK1/2 INHIBITOR MEK162 (BINIMETINIB) IN CHILDREN WITH LOW-GRADE GLIOMAS AND OTHER RAS/RAF PATHWAY-ACTIVATED TUMORS

BACKGROUND: Ras/Raf/MEK/ERK pathway activation is the primary driver of most pediatric low-grade gliomas (LGG). MEK162 is an orally bioavailable MEK1/2 inhibitor. OBJECTIVE: The primary objective of this first-in-children multi-institutional open-label dose-escalation trial was to determine the maxi...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Neuro Oncol
Main Authors: Robison, Nathan, Pauly, Jasmine, Malvar, Jemily, Gruber-Filbin, Mariella, de Mola, Rebecca Loret, Dorris, Kathleen, Bendel, Anne, Bowers, Daniel, Bornhorst, Miriam, Gauvain, Karen, Leary, Sarah, Diaz, Patricia, Tan, Yi Juin, Margol, Ashley, Dhall, Girish, Rosser, Tena, Bandopadhayay, Pratiti, Davidson, Tom, Ullrich, Nicole, Borchert, Mark, Nelson, Marvin, Sinai, Claire, Ligon, Keith, Sposto, Richard, Kieran, Mark
Formato: Artigo
Idioma:Inglês
Publicado em: Oxford University Press 2018
Assuntos:
Abstracts
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC6012544/
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1093/neuonc/noy059.385
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados